Has ADMA Biologics (ADMA) Outpaced Other Medical Stocks This Year?

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Adma Biologics (ADMA) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Adma Biologics is one of 1001 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Adma Biologics is currently sporting a Zacks Rank of #2 (Buy).Over the past three months, the Zacks Consensus Estimate for ADMA's full-year earnings has moved 3.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.Based on the most recent data, ADMA has returned 38.8% so far this year. In comparison, Medical companies have returned an average of -1.2%. This means that Adma Biologics is performing better than its sector in terms of year-to-date returns.Another Medical stock, which has outperformed the sector so far this year, is Agilon Health (AGL). The stock has returned 124.2% year-to-date.For Agilon Health, the consensus EPS estimate for the current year has increased 23.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).Looking more specifically, Adma Biologics belongs to the Medical - Biomedical and Genetics industry, which includes 508 individual stocks and currently sits at #77 in the Zacks Industry Rank. This group has lost an average of 1.8% so far this year, so ADMA is performing better in this area.Agilon Health, however, belongs to the Medical Services industry. Currently, this 58-stock industry is ranked #68. The industry has moved -0.8% so far this year.Adma Biologics and Agilon Health could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ADMA Biologics Inc (ADMA): Free Stock Analysis Report Agilon Health, Inc. (AGL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks